MRVI MARAVAI LIFESCIENCES HOLDINGS, INC.
Price Chart
Executive Summary
Maravai LifeSciences refinanced its prior credit agreement by entering into a new $150.0 million term loan and $30.0 million revolving credit facility, maturing June 2, 2032. Proceeds from the new term loan, combined with ~$98.5 million cash on hand, were used to repay $242.9 million in prior debt, reducing total debt by ~$92.9 million and extending the maturity from October 2027 to June 2032. The transaction materially reduces leverage, extends runway, and maintains liquidity, though a variable-rate interest structure introduces rate exposure.
Key Financial Metrics
Actionable Insight
Debt paydown eliminates near-term refinancing risk. Monitor upcoming quarterly filings for revenue/EPS trends and leverage ratio to see if full benefits materialize.
Key Facts
- New $150.0M term loan facility and $30.0M revolver, both maturing June 2, 2032; new term loan reduces outstanding debt from ~$242.9M to $150.0M.
- Proceeds from the new term loan plus ~$98.5M cash on hand used to fully prepay and terminate the prior Credit Agreement (due October 2027).
- Interest rate: Term SOFR + 5.00% per annum; stepdown to 4.75% if first lien net leverage ratio ≤ 3.00x.
- Financial covenant (springing): if revolver usage ≥ 40% of commitments, max first lien net leverage ratio of 6.50x.
- No material revenue or earnings figures reported in the filing.
- Credit agreement is secured by substantially all assets of material domestic subsidiaries and guaranteed by Topco and its material domestic subsidiaries.
Financial Impact
Debt reduced from ~$242.9M to $150.0M; maturity extended by ~5 years; $30.0M revolver provides undrawn liquidity.
Risk Factors
- Variable-rate exposure on $150M term loan tied to Term SOFR; rising rates increase interest expense.
- Prior historical mis-scoring at impact=6 (T+20 -4.60%) suggests the market may not fully price this as a strong credit event; calibrate expectations.
- $98.5M cash depletion reduces balance sheet cash buffer.
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001823239-26-000049 |
| Document: mrvi-20260602.htm | 0001823239-26-000049 |
| Document: finalmaravai-debtrefinance.htm | 0001823239-26-000049 |
| Document: 0001823239-26-000049-index-headers.html | 0001823239-26-000049 |
| Document: 0001823239-26-000049-index.html | 0001823239-26-000049 |
| Document: 0001823239-26-000049.txt | 0001823239-26-000049 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 3, 2026
3d ago
|
8-K
| $4.84 $4.99 | ▲ +3.10% | ▲ +2.70% | $5.02 (+3.72%) |
|
Apr 28, 2026
5w ago
|
DEFA14A
| — | awaiting T+1 | — | — |
|
Feb 25, 2026
14w ago
|
8-K
| $3.26 $3.56 | ▲ +9.20% | ▲ +9.75% | $5.02 (+53.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access